AMGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amgen Inc. (AMGN) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has some positive catalysts such as FDA approval for Uplizna and a solid dividend yield, the lack of strong bullish momentum, mixed analyst ratings, and balanced congressional trading activity suggest a hold position. The investor's impatience and unwillingness to wait for optimal entry points further reinforce this recommendation.
The stock's MACD is positively contracting, indicating a potential loss of bullish momentum. RSI is neutral at 37.261, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading close to its key support level (S1: 336.995), which could limit downside risk but does not strongly indicate an immediate buy opportunity.
FDA approval for Uplizna in IgG4-related disease and potential approval for generalized myasthenia gravis in February
Annual dividend yield of 2.85%, attractive for long-term investors.
Morgan Stanley projects Uplizna's market could double to over $10 billion in five years.
IRS audit dispute for 2016-2018, which could result in financial adjustments.
Mixed analyst ratings with some downgrades and lowered price targets.
Balanced congressional trading activity, not indicating strong confidence from influential figures.
Financial data for the latest quarter is unavailable, but analysts note that Q1 results were in line with expectations, with resilient performance in innovative portfolios offsetting weaknesses in mature products. However, the quarter is seasonally weak, and long-term growth remains uncertain.
Analyst ratings are mixed. Some firms, like Goldman Sachs, maintain a Buy rating but have lowered price targets due to ongoing IRS disputes. Others, like Erste Group, downgraded the stock to Hold, citing limited growth potential compared to competitors. The average sentiment leans neutral to slightly bearish.
